CA2858571C - Composition and method for neuropeptide s receptor (npsr) antagonists - Google Patents

Composition and method for neuropeptide s receptor (npsr) antagonists Download PDF

Info

Publication number
CA2858571C
CA2858571C CA2858571A CA2858571A CA2858571C CA 2858571 C CA2858571 C CA 2858571C CA 2858571 A CA2858571 A CA 2858571A CA 2858571 A CA2858571 A CA 2858571A CA 2858571 C CA2858571 C CA 2858571C
Authority
CA
Canada
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
mmol
nps
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2858571A
Other languages
English (en)
French (fr)
Other versions
CA2858571A1 (en
Inventor
Scott RUNYON
Yanan Zhang
Carla HASSLER
Brian GILMOUR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RTI International Inc
Original Assignee
RTI International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RTI International Inc filed Critical RTI International Inc
Publication of CA2858571A1 publication Critical patent/CA2858571A1/en
Application granted granted Critical
Publication of CA2858571C publication Critical patent/CA2858571C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
CA2858571A 2011-12-08 2012-12-06 Composition and method for neuropeptide s receptor (npsr) antagonists Active CA2858571C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161568540P 2011-12-08 2011-12-08
US61/568,540 2011-12-08
PCT/US2012/068257 WO2013086200A1 (en) 2011-12-08 2012-12-06 Composition and method for neuropeptide s receptor (npsr) antagonists

Publications (2)

Publication Number Publication Date
CA2858571A1 CA2858571A1 (en) 2013-06-13
CA2858571C true CA2858571C (en) 2021-03-16

Family

ID=48574884

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2858571A Active CA2858571C (en) 2011-12-08 2012-12-06 Composition and method for neuropeptide s receptor (npsr) antagonists

Country Status (7)

Country Link
US (1) US9150582B2 (https=)
EP (1) EP2788359B1 (https=)
JP (1) JP6381445B2 (https=)
AU (1) AU2012347758B2 (https=)
CA (1) CA2858571C (https=)
ES (1) ES2624853T3 (https=)
WO (1) WO2013086200A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017246706B2 (en) * 2016-04-04 2020-09-17 Research Triangle Institute Neuropeptide s receptor (NPSR) agonists
JOP20190060A1 (ar) * 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4917489B1 (https=) * 1970-01-22 1974-05-01
DE3469531D1 (en) * 1983-09-15 1988-04-07 Ciba Geigy Ag 5- and 6-azaphthalides, their mixture of isomers, process for their production and their use in recording materials which are sensitive to pressure and heat
WO1992009577A1 (en) * 1990-11-22 1992-06-11 Janssen Pharmaceutica N.V. Isonicotinic acid derivatives and related spiro compounds with herbicidal action
AU2001294239A1 (en) 2000-10-13 2002-04-22 Takeda Chemical Industries Ltd. Novel g protein-coupled receptor protein and dna thereof
US6642255B2 (en) 2001-01-11 2003-11-04 Bristol-Myers Squibb Pharma Company 1,2,-Disubstituted cyclic inhibitors of matrix metalloproteases and TNF-alpha
US9012407B2 (en) * 2004-04-23 2015-04-21 The Regents Of The University Of California Therapies which act on neuropeptide S receptors
US8541595B2 (en) * 2008-11-13 2013-09-24 Merch Sharp & Dohme Corp. Imidazoisoindole neuropeptide S receptor antagonists
WO2010056564A1 (en) * 2008-11-13 2010-05-20 Merck Sharp & Dohme Corp. Quinolone neuropeptide s receptor antagonists

Also Published As

Publication number Publication date
AU2012347758B2 (en) 2017-01-19
EP2788359A4 (en) 2015-06-10
US9150582B2 (en) 2015-10-06
EP2788359A1 (en) 2014-10-15
JP6381445B2 (ja) 2018-08-29
US20150057268A1 (en) 2015-02-26
AU2012347758A1 (en) 2014-06-05
ES2624853T3 (es) 2017-07-17
WO2013086200A1 (en) 2013-06-13
EP2788359B1 (en) 2017-03-01
JP2015500293A (ja) 2015-01-05
CA2858571A1 (en) 2013-06-13

Similar Documents

Publication Publication Date Title
KR101769999B1 (ko) Ｎｍｄａ 수용체 조절제 및 그의 용도
US6410548B2 (en) Spiropiperidine derivatives as melanocortin receptor agonists
CN102153562B (zh) 螺-吲哚酮化合物及其作为治疗剂的用途
JP6210993B2 (ja) Ｎｍｄａ受容体調節剤およびその使用
ES2308839T3 (es) Amidas n,n-disustituidas que inhiben la union de integrinas a sus receptores.
RU2572818C2 (ru) Производное тетрагидрокарболина
EP1085869A1 (en) Spiropiperidine derivatives as melanocortin receptor agonists
KR20060058104A (ko) 벤즈아미드 치환체를 갖는 사이클릭 아민 ｂａｃｅ-1억제제
AU2013230425A1 (en) Substituted heterocyclic acetamides as kappa opioid receptor (kor) agonists
KR20140129065A (ko) 축합 피롤디카복사미드 및 약제로서의 그의 용도
TW201321384A (zh) 作為鈣通道阻斷劑之經取代之八氫吡咯并［１，２－ａ］吡□磺醯胺
EP1301516A1 (en) Modulators of protein tyrosine phosphatases (ptpases)
CA2858571C (en) Composition and method for neuropeptide s receptor (npsr) antagonists
NO844560L (no) Nye amidforbindelser.
WO2006029210A2 (en) Acyclic 1,3-diamines and uses therefor
KR20010083109A (ko) 아미노산 유도체 및 이들을 유효 성분으로서 함유하는 약제
CA3018344C (en) Neuropeptide s receptor (npsr) agonists
RU2792034C2 (ru) Тетрагидроизохинолиновое соединение, способ его получения, фармацевтическая композиция, содержащая такое соединение, и его применение
CN115073449A (zh) 稠环杂环化合物及应用、含有其的药物组合物及应用
CA3018344A1 (en) Neuropeptide s receptor (npsr) agonists
HK1168104B (en) Spiro-oxindole compounds and their uses as therapeutic agents

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20171110

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241115

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241115

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251120

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251120